Some warning signs need prompt medical care

Heat, swelling, and fever need quick attention

Heat and swelling together can point to an infection. Fever makes the need for care more urgent. Spreading redness or fast-rising pain also needs attention. Don't try to work through these signs.

Watch for the same signs after any procedure. Call the treating clinician if the pain keeps rising. Calf swelling, redness, or pain can mean a blood clot. Get prompt help if you're also short of breath.

A hard injury may need urgent testing

Get help after an injury if you can't bear weight. A clear change in the joint's shape also needs care. Sudden loss of movement is another warning sign. Don't drive if you feel faint or unsteady.

New numbness or weakness needs prompt care too. Loss of bladder or bowel control with back pain is urgent. Pressure on nerves can cause those problems. A planned joint visit isn't the right first stop.

A routine visit fits slow, steady soreness

A regular exam fits soreness that builds over time. Write down each medicine and earlier treatment. Tell the clinician about pain at night or a past cancer. You'll get safer advice when the clinician knows your history.

A regular visit can also cover planned joint care. QC Kinetix offers concentrated PRP, made by gathering more platelets from your blood into a smaller amount before using it in the aching joint. This isn't emergency care or a replacement for needed surgery. The clinician must first decide whether the procedure fits you.

Sources

1. The OARSI non-surgical management guideline evaluated 60 interventions with GRADE methodology and built its recommendations around core treatments - structured exercise, weight management and self-management education - for every patient with knee osteoarthritis, regardless of what else is added.

   Bannuru RR, et al. — OARSI guidelines for the non-surgical management of knee, hip, and polyarticular osteoarthritis. Osteoarthritis Cartilage, 2019. DOI: 10.1016/j.joca.2019.06.011.

2. A retrospective comparison of 523 bone marrow aspiration procedures against 435 open iliac crest bone graft harvests found aspiration significantly reduced complications - relevant because marrow aspiration for a joint injection is a real procedure with a real, if low, complication rate.

   Hernigou P, et al. — Morbidity of graft harvesting versus bone marrow aspiration in cell regenerative therapy. Int Orthop, 2014. DOI: 10.1007/s00264-014-2318-x.

3. A CDC public health investigation confirmed culture-positive bacterial infections in 20 patients who received umbilical cord blood-derived products marketed as stem cell treatment between August 2017 and September 2018; whole-genome sequencing matched patient isolates to the product.

   Hartnett KP, et al. — Investigation of Bacterial Infections Among Patients Treated With Umbilical Cord Blood-Derived Products Marketed as Stem Cell Therapies. JAMA Netw Open, 2021. DOI: 10.1001/jamanetworkopen.2021.28615.

4. FDA states in its consumer alert that the only FDA-approved stem cell products in the United States are blood-forming stem cells derived from umbilical cord blood, approved for disorders of the blood-forming system, and that NONE of these products - stem cells, stromal vascular fraction, umbilical cord blood, Wharton's jelly or amniotic fluid - has been approved for the treatment of any orthopedic condition, including osteoarthritis, tendonitis, disc disease, tennis elbow, back pain, hip pain, knee pain, neck pain or shoulder pain.

   US Food and Drug Administration, Center for Biologics Evaluation and Research — Consumer Alert on Regenerative Medicine Products Including Stem Cells and Exosomes. , 2020.

5. In a 480-patient, four-arm, multicenter randomized phase 2/3 trial, none of three orthobiologic cell injections - autologous bone marrow aspirate concentrate, autologous adipose stromal vascular fraction, or allogeneic umbilical cord tissue-derived mesenchymal stromal cells - was superior to any other, or to a corticosteroid injection control, on pain at 12 months.

   Mautner K, et al. — Cell-based versus corticosteroid injections for knee pain in osteoarthritis: a randomized phase 3 trial. Nat Med, 2023. DOI: 10.1038/s41591-023-02632-w.